Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitis
The similar characteristics of ICI-pneumonitis across malignancies support the generalizability of management strategies. Approximately one-fifth of patients successfully continued ICI therapy after pneumonitis. Systematic radiological surveillance and appropriate severity-based treatment may help optimize outcomes in patients receiving ICI therapy.
Authors
- Ryosuke Matsukane (ORCID: https://orcid.org/0000-0001-5444-2443)
- Kazuya Tsubouchi (ORCID: https://orcid.org/0000-0003-0145-8745)
- Sai Yasukochi (ORCID: https://orcid.org/0000-0003-2651-3472)
- Hiroaki Ogata (ORCID: https://orcid.org/0000-0001-5216-1576)
- Kouji Masumoto (ORCID: https://orcid.org/0000-0002-0312-9403)
- Mayako Uchida
- Isamu Okamoto
- Tomotsugu Takano
Institutions
- Kyushu University (JP)
- National Kyushu Medical Center (JP)
- Kyushu University Hospital (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1007/s00262-026-04375-2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00